Scholarlink

<p>The Hippo pathway is considered crucial in regulatory, significant cellular processes like proliferation and apoptosis, accordingly maintaining the tissue homeostasis of an organism. Its disordered state has been widely associated with head and neck cancer during its initiation and progression processes. This review focuses on clinical evidence that links Hippo signaling with HNC, particularly where increased YAP/TAZ expression is associated with adverse prognosis, more advanced disease stage, and greater chemoresistance and radioresistance. The diverse approaches designed to target the Hippo pathway- small molecule inhibitors, RNA therapies, and combination therapies- seem promising in preclinical models, have significant challenges from tumor heterogeneity, compensatory signaling, and off-target effects. Subsequent research must focus on incorporating multi-omics, employing personalized therapies, and creating sophisticated delivery systems to enhance treatment effectiveness. Therapeutic targeting of the Hippo signaling system in HNC has enormous promise, and more research might lead to novel treatment approaches that enhance clinical results.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hippo Pathway Dysregulation in Head and Neck Cancer: A Molecular Key To Future Diagnostic System

  • 期刊论文

  • 发表日期：

    2025年7月26日

查看全文
  • Kalaiselvi Krishnamoorthy

摘要

The Hippo pathway is considered crucial in regulatory, significant cellular processes like proliferation and apoptosis, accordingly maintaining the tissue homeostasis of an organism. Its disordered state has been widely associated with head and neck cancer during its initiation and progression processes. This review focuses on clinical evidence that links Hippo signaling with HNC, particularly where increased YAP/TAZ expression is associated with adverse prognosis, more advanced disease stage, and greater chemoresistance and radioresistance. The diverse approaches designed to target the Hippo pathway- small molecule inhibitors, RNA therapies, and combination therapies- seem promising in preclinical models, have significant challenges from tumor heterogeneity, compensatory signaling, and off-target effects. Subsequent research must focus on incorporating multi-omics, employing personalized therapies, and creating sophisticated delivery systems to enhance treatment effectiveness. Therapeutic targeting of the Hippo signaling system in HNC has enormous promise, and more research might lead to novel treatment approaches that enhance clinical results.